Published in Eur Heart J on June 17, 2008
Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol (2012) 1.25
Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol (2011) 1.01
Endothelin. Pharmacol Rev (2016) 0.95
Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag (2009) 0.94
The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax (2015) 0.90
Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Ther Clin Risk Manag (2010) 0.89
The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract (2014) 0.89
Endothelin receptors and their antagonists. Semin Nephrol (2015) 0.87
Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatr Pulmonol (2012) 0.82
Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des Devel Ther (2009) 0.79
Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice. J Am Soc Nephrol (2017) 0.79
Rosiglitazone Attenuated Endothelin-1-Induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension via Differential Regulation of ET-1 Receptors. PPAR Res (2014) 0.78
Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension. Respir Res (2011) 0.78
Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. Vasc Health Risk Manag (2011) 0.77
Selective endothelin-A receptor blockade attenuates endotoxin-induced pulmonary hypertension and pulmonary vascular dysfunction. Pulm Circ (2014) 0.76
Does targeting the lipophilic milieu provide advantages for an endothelin antagonist? Mol Interv (2009) 0.75
Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics. J Thorac Cardiovasc Surg (2010) 0.75
[Pulmonary arterial hypertension in collagenoses]. Z Rheumatol (2009) 0.75
Insights into ET(A) subtype selectivity of benzodiazepine endothelin receptor antagonists by 3D-QSAR approaches. J Mol Model (2011) 0.75
A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 27.60
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med (1991) 13.21
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Treatment of pulmonary arterial hypertension. N Engl J Med (2004) 6.88
Pulmonary arterial hypertension. N Engl J Med (2004) 6.69
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J (2004) 3.51
Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation (2006) 3.05
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med (2003) 2.64
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol (2006) 2.42
A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J (2007) 2.42
Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol (2000) 2.35
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J (2006) 2.34
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell (2004) 2.29
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther (2001) 2.10
Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2005) 1.82
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther (2003) 1.79
Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J (2007) 1.75
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis (2007) 1.72
Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes. Circ Res (1991) 1.71
Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 1.69
Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol (1995) 1.65
Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 1.61
Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int (2001) 1.60
Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol (2007) 1.52
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet (1995) 1.51
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest (2001) 1.49
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol (1997) 1.47
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2004) 1.40
ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med (2002) 1.39
Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med (1997) 1.37
Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum (1991) 1.36
Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J (2007) 1.32
Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension (1997) 1.31
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol (2005) 1.29
Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol (2005) 1.29
ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol (1995) 1.28
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation (2004) 1.27
End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol (2004) 1.24
Vascular biology of endothelin. J Cardiovasc Pharmacol (1998) 1.24
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther (1996) 1.24
Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med (2005) 1.23
Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol (1985) (1995) 1.22
Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation (1998) 1.22
Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway. J Clin Invest (1995) 1.10
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol (2005) 1.09
Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem (1994) 1.08
Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res (1996) 1.03
Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol (1995) 1.03
Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol (2003) 1.02
Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation (2001) 1.02
Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J (2000) 1.02
The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol (1992) 1.01
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest (2008) 1.00
Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol Heart Circ Physiol (2003) 1.00
Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos (2007) 0.98
Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol (1998) 0.97
Fluorescence resonance energy transfer analysis reveals the existence of endothelin-A and endothelin-B receptor homodimers. J Cardiovasc Pharmacol (2004) 0.97
Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int (1995) 0.97
Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors. Br J Pharmacol (1995) 0.96
Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions. J Vasc Res (2007) 0.95
Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension (2001) 0.95
Endothelin-1 stimulates human colonic myofibroblast contraction and migration. Gut (2002) 0.94
The value of approved therapies for pulmonary arterial hypertension. Am Heart J (2007) 0.94
The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol (2001) 0.93
Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev (2006) 0.92
Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation (2000) 0.91
Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol (1999) 0.90
A review of pulmonary arterial hypertension: role of ambrisentan. Vasc Health Risk Manag (2007) 0.90
The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol (1997) 0.89
Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest (2006) 0.88
Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother (2007) 0.88
Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J (1998) 0.88
Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res (2000) 0.87
Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. Circ J (2007) 0.86
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J Heart Lung Transplant (2001) 0.85
Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension (1996) 0.84
Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol (1995) 0.84
Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant (2007) 0.83
Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists. J Med Chem (2004) 0.83
Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm Pharmacol Ther (2000) 0.81
Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med (2003) 0.81
Endothelin-1 inhibits endothelin-converting enzyme-1 expression in cultured rat pulmonary endothelial cells. Circulation (1998) 0.80
Endothelin-1 induces an increase in total protein synthesis and expression of the smooth muscle alpha-actin gene in vascular smooth muscle cells. Life Sci (1996) 0.79
Endothelin receptor antagonists and their developing role in cardiovascular therapeutics. Can J Cardiol (2000) 0.79
Changes in collagen metabolism in response to endothelin-1: evidence for fibroblast heterogeneity. Int J Biochem Cell Biol (1996) 0.78
Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. Eur J Clin Invest (2006) 0.78
Are selective endothelin A receptor antagonists better than mixed antagonists? J Cardiovasc Pharmacol (2001) 0.77
Angiotensin II type 1 and endothelin type A receptor antagonists modulate the extracellular matrix regulatory system differently in diastolic heart failure. J Hypertens (2003) 0.76
Cohort profile: the study of health in Pomerania. Int J Epidemiol (2010) 4.38
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation (2013) 3.90
High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis (2004) 3.55
Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation (2009) 3.28
The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab (2010) 3.12
Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis (2002) 2.33
Mobile applications for diabetics: a systematic review and expert-based usability evaluation considering the special requirements of diabetes patients age 50 years or older. J Med Internet Res (2014) 2.03
Accuracy of anthropometric indicators of obesity to predict cardiovascular risk. J Clin Endocrinol Metab (2006) 1.87
Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol (2006) 1.76
Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med (2002) 1.72
Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation (2002) 1.70
Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol (2011) 1.58
Peripheral arterial disease as an independent predictor for excess stroke morbidity and mortality in primary-care patients: 5-year results of the getABI study. Cerebrovasc Dis (2010) 1.55
Elevated risk profile of women in secondary prevention of coronary artery disease: a 6-year survey of 117,913 patients. J Womens Health (Larchmt) (2009) 1.53
Association of low ankle brachial index with high mortality in primary care. Eur Heart J (2006) 1.53
Prevalence, recognition and management of depression in primary care in Germany: the Depression 2000 study. Hum Psychopharmacol (2002) 1.51
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol (2012) 1.48
Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens (2004) 1.48
Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol (2007) 1.46
High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens (2004) 1.43
Effect of inhaled iloprost during off-medication time in patients with pulmonary arterial hypertension. Respiration (2007) 1.42
Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens (2011) 1.42
Drug interactions with angiotensin receptor blockers. Expert Opin Drug Saf (2005) 1.41
Assessing cutoff values for increased exercise blood pressure to predict incident hypertension in a general population. J Hypertens (2015) 1.39
Pulmonary arterial hypertension and right heart failure--a late-onset complication after cardiac catheterization. Catheter Cardiovasc Interv (2009) 1.38
Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit (2005) 1.26
Reproducibility and reliability of the ankle-brachial index as assessed by vascular experts, family physicians and nurses. Vasc Med (2007) 1.23
Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vasc Health Risk Manag (2009) 1.22
High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. J Clin Psychiatry (2003) 1.17
Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J (2005) 1.13
Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther (2005) 1.09
Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J (2005) 1.09
Simultaneous determination of three anticonvulsants using hydrophilic interaction LC-MS. J Sep Sci (2009) 1.07
Profound influence of different methods for determination of the ankle brachial index on the prevalence estimate of peripheral arterial disease. BMC Public Health (2007) 1.06
Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study. J Immunother (2009) 1.05
Impaired peripheral endothelial function in severe idiopathic pulmonary hypertension correlates with the pulmonary vascular response to inhaled iloprost. Am Heart J (2007) 1.01
Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med (2008) 1.00
Atopic eczema and attention-deficit/hyperactivity disorder in a population-based sample of children and adolescents. JAMA (2009) 1.00
The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res (2007) 1.00
Clinical practice and recent recommendations in hypertension management--reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin (2007) 1.00
Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl) (2003) 0.99
Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med (2010) 0.98
Cohort profile: Greifswald approach to individualized medicine (GANI_MED). J Transl Med (2014) 0.97
Influence of age, sex, body size, smoking, and beta blockade on key gas exchange exercise parameters in an adult population. Eur J Cardiovasc Prev Rehabil (2010) 0.97
Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle-brachial index (ABI) and high homocysteine level. Atherosclerosis (2005) 0.96
Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol (2009) 0.95
[Antimicrobial and clinical efficacy of nitrofurantoin in the treatment of acute lower urinary tract infections in adults]. Med Klin (Munich) (2010) 0.95
Potential role of flavonoids in the prevention of intestinal neoplasia: a review of their mode of action and their clinical perspectives. Int J Gastrointest Cancer (2005) 0.94
Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort. Clin Res Cardiol (2009) 0.94
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum (2008) 0.94
Economic burden of patients with various etiologies of chronic systolic heart failure analyzed by resource use and costs. Int J Cardiol (2012) 0.93
Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag (2007) 0.93
Obesity and the risk for mental disorders in a representative German adult sample. Eur J Public Health (2006) 0.93
Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists. Clin Res Cardiol (2011) 0.93
Acceptance factors of mobile apps for diabetes by patients aged 50 or older: a qualitative study. Med 2 0 (2015) 0.92
Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin. Clin Ther (2007) 0.92
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Ann Rheum Dis (2010) 0.92
Laparoscopic or open conventional cholecystectomy: clinical and economic considerations. Eur J Surg (2002) 0.92
Effects of caffeine on topographic quantitative EEG. Neuropsychobiology (2002) 0.92
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol (2009) 0.91
Potentially inappropriate prescribing for elderly outpatients in Germany: a retrospective claims data analysis. Int J Clin Pharmacol Ther (2012) 0.91
Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. World J Gastroenterol (2008) 0.91
Exercise capacity affects quality of life in patients with pulmonary hypertension. Lung (2013) 0.90
Mental health problems, obstructive lung disease and lung function: findings from the general population. J Psychosom Res (2011) 0.90
Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: prospective non-interventional study. Int J Cardiol (2012) 0.90
Are serum thyrotropin levels within the reference range associated with endothelial function? Eur Heart J (2008) 0.89
Prescriptions of systemic antibiotics for children in Germany aged between 0 and 6 years. Pharmacoepidemiol Drug Saf (2003) 0.89
Subcutaneous implantation of a new intravenous pump system for prostacyclin treatment in patients with pulmonary arterial hypertension. Heart Lung (2012) 0.89
Relation of respiratory muscle strength, cachexia and survival in severe chronic heart failure. J Cachexia Sarcopenia Muscle (2013) 0.89
Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease. Future Cardiol (2007) 0.88
Characteristics, management and attainment of lipid target levels in diabetic and cardiac patients enrolled in Disease Management Program versus those in routine care: LUTZ registry. BMC Public Health (2009) 0.87
Lung function reference values in different German populations. Respir Med (2010) 0.87
Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension. Int J Cardiol (2012) 0.86
The effects of bupropion on heart rate variability in healthy volunteers. J Clin Psychopharmacol (2005) 0.86
Prevalence of low male testosterone levels in primary care in Germany: cross-sectional results from the DETECT study. Clin Endocrinol (Oxf) (2008) 0.85
High prevalence of peripheral arterial disease but low antiplatelet treatment rates in elderly primary care patients with diabetes. Diabetes Care (2003) 0.85
Standard PAH therapy improves long term survival in CTEPH patients. Clin Res Cardiol (2010) 0.84
[DRG Introduction in Germany. Options for action of hospitals]. Med Klin (Munich) (2005) 0.84
Association of testosterone levels with endothelial function in men: results from a population-based study. Arterioscler Thromb Vasc Biol (2011) 0.84
Outpatient care and medical treatment of children and adults with atopic eczema. J Dtsch Dermatol Ges (2008) 0.84
Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients. PLoS One (2012) 0.84
Spontaneous haemoptysis as a late complication of plombage in a tuberculosis patient. Wien Med Wochenschr (2011) 0.84
Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study. Int J Methods Psychiatr Res (2005) 0.84
Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis (2008) 0.83
Association between serum insulin-like growth factor (IGF) I and IGF binding protein-3 and lung function. J Clin Endocrinol Metab (2009) 0.83
Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol (2011) 0.83
HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients. Blood Press (2004) 0.83
Respiratory muscle dysfunction in congestive heart failure--the role of pulmonary hypertension. Int J Cardiol (2010) 0.83
Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis. Angiology (2003) 0.83